Concepts to Practice: The Evolving Landscape of Congenital Adrenal Hyperplasia Management Strategies
(5)
Image For Activity Cover
Availability
On-Demand
Expires on Dec 31, 2024
Cost
$0.00
Credit Offered
1.5 AMA PRA Category 1 Credits
1.5 ABIM-MOC Points
1.5 Participation Credits
  • Description
  • Target Audience
  • Learning Objectives
  • Accreditation Statement
  • Faculty and Disclosures
  • ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
  • Recommended

Congenital adrenal hyperplasia (CAH) is a group of genetic conditions that adversely affect the adrenal glands, resulting in reduced cortisol synthesis and elevated androgen levels. Unfortunately, many children and adults with CAH commonly experience undesired adverse effects from current glucocorticoid treatments. Emerging treatments are being evaluated for their potential to reduce the burden of glucocorticoid dosing that could greatly improve care and quality of life for patients with CAH. Please join our experts in this live 90-minute symposium where they will discuss screening and diagnosis of CAH, including challenges with current glucocorticoid treatment, emerging CAH treatments, and strategies for management of CAH within a comprehensive care team environment.

  • Endocrinologists
  • Primary care physicians (PCPs)
  • Nurse practitioners (NPs)
  • Physician assistants (PAs)
  • Pediatricians
Other clinicians who treat patients with congenital adrenal hyperplasia (CAH)
  • Upon completion of this activity, learners will have:

    • Increased knowledge regarding the
      • Clinical presentation and diagnosis of CAH
      • Treatment strategies for classic CAH
      • Clinical data/MOA of emerging treatments for CAH
    • Greater confidence in their ability to implement currently available strategies for management of CAH within a comprehensive care team environment

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Endocrine Society and Medscape. The Endocrine Society is accredited by the ACCME to provide continuing medical education for physicians. 

AMA PRA Category 1 Credit

The Endocrine Society designates each activity in this course for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.


Maintenance of Certification (MOC)
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.50 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


AAPA Credit

Medscape has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.





For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org

Richard Joseph Auchus, MD, PhD – Program Chair
University of Michigan
Ann Arbor, MI

Phyllis Witzel Speiser, MD
Donald and Barbara Zucker School of Medicine/Northwell
Hempstead, NY

Anand Vaidya, MD, MMSc
Brigham and Women’s Hospital

Boston, MA
              

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

  • Richard Joseph Auchus, MD, PhD

    Consultant - Quest Diagnostics; Corcept Therapeutics; Novartis Pharmaceuticals; Xeris Pharmaceuticals; Crinetics Pharmaceuticals; Adrenas Therapeutics; PhaseBio Pharmaceuticals; Novo Nordisk; Neurocrine Biosciences; Recordati Rare Diseases; H Lundbeck A/S Takeda; Development Center Americas, Inc

    Contracted Research - Novartis Pharmaceuticals Neurocrine Biosciences Spruce Biosciences Corcept Therapeutics Diurnal, LTD Sparrow Pharmaceuticals


  • Phyllis Witzel Speiser, MD: 

    Consultant - Member, Adrenas Therapeutics Gene Therapy Data Safety Monitoring Committee; 

    Research Funding - Neurocrine Phase 3 Site investigator for Pediatric Crinecerfont Trial


  • Anand Vaidya, MS, MMSc: 

    Consultant - Mineralys (ended Oct 2022) Corcept Pharmaceuticals (ended Jan 2022) HRA Pharma (ended Jan 2022)

The following faculty reported no relevant financial relationships:

The following committee member who planned and reviewed content for this activity reported relevant financial relationships: 

Athanasios Bikas, MD
Brigham and Women’s Hospital

Brookline, MA

The following member who reviewed content for this activity reported relevant financial relationships:


The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.

This educational activity is supported by educational grant from NEUROCRINE BIOSCIENCES, INC.
   
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
      
   
Android App Download IOS App Download Powered By